Background: Current guidelines for epicardial catheter ablation for ventricular tachycardia (VT) advocate that epicardial access is avoided in anticoagulated patients and should be performed prioronse to heparinisation. Recent studies have shown that epicardial access may be safe in heparinised patients. However, no data exist for patients on oral anticoagulants. We investigated the safety of obtaining epicardial access on uninterrupted warfarin.
INTRODUCTION
Catheter ablation of ventricular tachycardia (VT) is increasingly used as a therapeutic option in patients with sustained VT. 1, 2 This is typically performed endocardially initially, 2, 3 with an epicardial approach conventionally used on a subsequent occasion when an endocardial substrate has not been identified at the index procedure 4 , although a combined approach is being undertaken increasingly during the index procedure. 5 Epicardial access might be obtained at the outset in cases where an epicardial substrate is more likely e.g. arrhythmogenic right ventricular cardiomyopathy, dilated cardiomyopathy and cardiac sarcoidosis. 6 Percutaneous epicardial access has become an established technique allowing access to the epicardial surface for mapping and ablation. 7, 8 Epicardial ablation is a relatively safe approach with a major complication rate around 4 -8% in tertiary centres. 9 Consensus guidelines recommend that epicardial access is avoided in anticoagulated patients and should be performed prior to systemic heparinisation. 2 Recent studies have shown that epicardial access may be safe in heparinised patients. 10 However, there are no data supporting the safety of epicardial ablation in patients on oral anticoagulants. This is at odds with modern ablation for atrial fibrillation where benefits to periprocedural uninterrupted anticoagulation are demonstrable. 11, 12 In this study we report our experience of obtaining epicardial access on uninterrupted warfarin. We compared patients who underwent epicardial VT ablation (post systemic heparinisation) while on uninterrupted warfarin to those who were not taking an oral anticoagulant in a case-control study to determine the risks and benefits of both approaches.
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METHODS
Study design:
Retrospective, case-control study of patients undergoing epicardial catheter ablation for VT. Consecutive patients in whom epicardial access was attempted after heparinisation were included in the study. Patients on warfarin were compared in a case-control study to those not on any oral-anticoagulant. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the institution's human research committee. All patients were recruited at a single centre (The Barts Heart Centre, St Bartholomew's Hospital).
Prior to the procedure, all patients gave written informed consent.
Study patients:
All patients undergoing catheter ablation for VT in whom epicardial access was attempted after heparinisation (with or without uninterrupted warfarin) were included in this study. Consecutive patients from April 2013 to April 2015 were included.
Patients who underwent epicardial ablation while on uninterrupted warfarin (Warfarin Group) were compared to those who were not taking an oral anticoagulant (Nowarfarin group). Patients in whom epicardial access was attempted prior to heparinisation were excluded from the study. No patient underwent epicardial ablation on a NOAC during the study period.
Catheter ablation procedure:
All procedures were carried out under intravenous moderate sedation. Patients were heparinised (after obtaining vascular access) with a target activated clotting time (ACT) of 300 -350 seconds. Anticoagulation was not reversed in patients on uninterrupted warfarin. 7F and 8F sheaths were placed in the right femoral vein (unless there was a specific contraindication) and a 4F sheath in the right femoral artery, allowing continuous arterial pressure monitoring. Electroanatomical mapping of the left ventricle was performed anterogradely following puncture of the inter-atrial septum.
When retrograde access was sought in addition, an 8F sheath substituted the 4F arterial sheath. Carto 3 was used in all cases.
Epicardial access was obtained in fully heparinised patients (with or without warfarin) via a percutaneous sub-xiphoid approach using the technique described by Sosa et al. 7 In brief, either an 18G epidural Tuohy needle, or a similar introducer needle, was advanced under local anaesthesia towards the cardiac silhouette in an anteroposterior or left anterior oblique projection, aiming for the inferior border of the heart (either anteriorly or posteriorly). The needle was advanced until a 'give' was felt as the needle punctured the parietal pericardium, a small injection of contrast (<2mls) confirmed that the needle tip was within the pericardial space. A 0.032 inch guide wire was then advanced and either a short 8F sheath or a 9F steerable sheath (Agilis, St Jude Medical Inc, NM, USA) was used to secure access and aid catheter manipulation. Epicardial mapping and ablation was performed using a Smart Touch radiofrequency ablation catheter. During mapping, a continuous flow of 2 mL/min was used and during ablation the flow was increased to 10-30 mL/min. Fluid was periodically aspirated from a side port of the sheath to prevent accumulation of pericardial fluid during the procedure. Where necessary, coronary angiography was performed to define the proximity of the proposed ablation site to epicardial coronary arteries. Heparin reversal with protamine was not performed prior to obtaining pericardial access to facilitate further endocardial mapping and ablation if required after epicardial mapping. 10 Post-procedure, the catheters were removed and the pericardial sheath exchanged for a pigtail catheter. The catheter was aspirated to dryness and absence of residual pericardial fluid confirmed on a transthoracic echocardiogram.
Hydrocortisone (100mg) was administered into the pericardial space via the pericardial drain, which was clamped for 15 minutes before being left on free drainage overnight. An echocardiogram was repeated 12hrs post-procedure and if the absence of a pericardial effusion was confirmed then a further bolus of hydrocortisone (100 mg) was administered and the pericardial drain removed.
Follow up:
Patients were typically discharged from hospital on the second day post ablation (i.e. approximately 48 hours post procedure). Patients were followed up in clinic at three months following their ablation regarding study endpoints with an ICD check in those with a device in situ. Additional review of medical notes and electronic health records was carried out to obtain a complete dataset.
Study end points:
The primary end point of the study was a composite of major and minor procedural Secondary endpoints included acute procedural success and freedom from arrhythmia at 3-month follow-up. Acute ablation success was defined as an identifiable epicardial target and non-inducibility was not sought in all patients.
Statistical analyses:
Data were analysed on an intention-to-treat basis. All analyses were carried out using SAS version 9.3, statistical software. Continuous data were presented as mean ± standard deviation or median (range) if not normally -distributed. Categorical data were reported as a percentage. Continuous data were compared using unpaired ttest (if normally-distributed) and Mann-Whitney U test if not normally-distributed.
Categorical data were compared using chi-square test. A p-value of less than 0.05 was considered significant.
RESULTS
Study patients:
46 consecutive patients undergoing VT ablation with epicardial access being performed post heparinisation were included in the study. 13 of these were on uninterrupted warfarin at the time of the procedure (Warfarin group), whereas 33
were not on any oral anticoagulants (No-warfarin group). Within the limitations of the current study design, the two groups were appropriately matched with regard to clinical and procedural characteristics other than for AF (92.3 versus 9.1%, p < 0.0001) and INR (2.30 ± 0.70 versus 1.04 ± 0.07, p < 0.0001). In the warfarin group, the CHA2DS2-VASc ranged from 2 -4 (mean ± SD, 2.5 ± 0.7) and the majority (92.3%) of patients were anticoagulated for stroke risk prevention on the background of atrial fibrillation. No patient had a history of previous cardiac surgery. The clinical characteristics of the two groups are shown in Table 1 .
Procedural data:
The vast majority of procedures were performed as emergent or emergency cases. There was no significant difference in the procedural data between the two groups - Table 2 .
Study endpoints:
Primary endpoint -Complications
There were no deaths in this patient cohort and no patient required surgical intervention. None of the patients suffered coronary artery damage or abdominal visceral laceration. A higher proportion of patients in the warfarin group had a drop of haemoglobin of >2g/dL and delayed pericardial drain removal (>24 hours postprocedure) compared to the no-warfarin group (n = 5, 38.5% versus n = 9, 27.3%, p = 0.74 and n = 1, 7.8% versus n = 1, 3.03%, p = 0.47). However, none of these patients required blood transfusion.
There was no significant difference in the overall procedural complication rate (warfarin versus no-warfarin group), including death/surgical intervention (0 versus 0), coronary artery damage (0 versus 0), RV puncture (30.8% versus 15.2%, p = 0.23), >2g/dL drop in Hb (38.5% versus 27.3%, p = 0.74) and delayed pericardial drain removal (7.8% versus 3.03%, p = 0.47) - Figure 1 .
Secondary endpoint -Procedural Success
Acute ablation success (defined as an identifiable epicardial target and termination of arrhythmia) was similar in both groups (warfarin versus no-warfarin 69.2% versus 72.7%, p = 0.81). Non-inducibility of VT was not sought in all cases. 
DISCUSSION
In the present study we report our experience of obtaining epicardial access in patients on uninterrupted warfarin. The main findings of the study indicate that the risk of obtaining epicardial access do not seem to be significant in patients anticoagulated with warfarin and heparinised with a therapeutic ACT. We found no significant impact on the rate of bleeding complications or any difference in the overall complication rate of epicardial VT ablation between the warfarin and nowarfarin group.
Although catheter ablation for VT is an established technique, there is wide variation in success rates due to the high complexity of VT substrate and procedure related complications. [13] [14] [15] High recurrence rates post ablation are common and 15-20% of patients require epicardial ablation for arrhythmia termination and resolution of symptoms. [16] [17] [18] In our cohort of patients nearly 59% were symptom free at three months follow-up post epicardial ablation and recurrence of VT requiring a further procedure was low (8.3% in warfarin and 22.6% in no-warfarin group). These data are comparable to those of previously-published trials, albeit with a shorter follow-up period. 19, 20 Hence, epicardial ablation was effective in this cohort of patients and the procedural success did not appear to be affected by the patients' anticoagulation status.
Obtaining access to the pericardial space and epicardial surface of the heart comes with its own risks including significant pericardial bleeding and damage to adjacent structures including the liver. 4, 17 To prevent these complications, current guidelines suggest that pericardial access should be avoided in anticoagulated patients. 2 This approach poses procedural dilemmas as epicardial targets are often sought after endocardial mapping (which requires systemic heparinisation).
Pericardial access would therefore need to be obtained from the outset prior to systemic anticoagulation or at a second procedure. Alternatively heparin and/or warfarin could be reversed before obtaining pericardial access. However, reversal of heparin precludes further endocardial mapping and ablation. Furthermore, discontinuation of warfarin prior to the procedure or reversal of warfarin intraprocedurally has significant implications for periprocedural management and potential adverse events. Data from AF ablation suggests optimal management is to continue warfarin without interruption. 11, 12 The ideal approach, if it were not shown to unduly increase risk, would involve combining endocardial and epicardial mapping in the same procedure and hence achieving pericardial access in heparinised patients without discontinuing oral anticoagulants (if any).
Previous published data in a small cohort of patients have shown that pericardial access is feasible in heparinised patients. 10 The present study shows for the first time that epicardial ablation can be performed safely and effectively in patients on warfarin and peri-procedural systemic heparinisation. We found that the overall complication rate was low and consistent with previously published data. 9 There were no deaths in this patient cohort and no patient required surgical intervention. Moreover, none of the patients suffered coronary artery damage or abdominal visceral laceration. More patients on uninterrupted warfarin had a drop of haemoglobin > 2g/dL and more had delayed pericardial drain removal (7.8% versus 3.03%). These small differences did not reach significance given the small numbers and it would require a much larger study to show whether this difference is real. Importantly, none of these patients had other major bleeding complications or required a blood transfusion. Whilst this is encouraging, it provides no data on the impact of oral anticoagulation on the severity of a major bleeding event should it occur. However, in the event of bleeding, rapid and complete reversal of warfarin is feasible using synthetic clotting factor concentrates. 21 On the other hand, the benefits of performing epicardial ablation on uninterrupted warfarin (in addition to systemic heparinisation) are manifold. It is a very attractive approach for patients at high risk of thromboembolic phenomena in whom warfarin would ideally not be discontinued. Discontinuation of warfarin would require more frequent INR measurements when warfarin is re-started post procedure. The dosing can be complex and lead to under or over anticoagulation.
It seems that it is feasible to continue uninterrupted warfarin for VT ablation, and that should epicardial access be desired after heparinisation and endocardial mapping/ablation, then it can be safely obtained without the need to reverse either heparin or warfarin. Obtaining epicardial access with peri-procedural heparinisation allows the operator to combine endocardial and epicardial mapping in the same procedure. This approach avoids obtaining access at the outset and therefore negates the additional risk of epicardial puncture if endocardial ablation has been successful.
STUDY LIMITATIONS
These data are limited to a small cohort of patients in a single centre. The two groups were approximately matched, albeit a trend towards greater age and co-morbidity in the anticoagulated group. Whilst the warfarinised group was older and frailer, with the oldest patient being 88yrs. We recognize that as yet the safety and efficacy of VT ablation in the elderly and frail patients in general remains unclear. Given the limitations of clinical practice and the low event rate for bleeding complications, it is unlikely that a randomised trial will be performed in this area. Large multicentre studies are required to confirm these findings and establish the safety of periprocedural anticoagulation during epicardial VT ablation. Nevertheless, these data give no signal of increased risk with this strategy. All oral anticoagulation was performed with warfarin, the safety of newer anticoagulants in this setting remains unknown.
CONCLUSIONS
This study suggests that epicardial access can be achieved without significant increased risk in patients on uninterrupted warfarin in addition to systemic heparinisation (with therapeutic INR and ACT). Although the risk and benefit of this approach remains incompletely defined, these data may be reassuring for physicians considering uninterrupted warfarin in patients with a strong indication for periprocedural anticoagulation. Larger multicentre studies are required to confirm these findings and to test the safety of newer oral anticoagulants in this setting. 
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FIGURE LEGENDS
Figure 1: Procedural Complications
Box-plot showing complications in the warfarin (n=13) and no-warfarin (n=33) group.
There was no significant difference in the complication rates between the warfarin and no-warfarin group: Hb drop>2g/dL (38.5% versus 27.3%, p = 0.74), RV puncture (30.8% versus 15.2%, p = 0.23), delayed pericardial drain removal (7.8% versus 3.03%, p = 0.47). There were no reported deaths or coronary artery damage in both groups.
Figure 2: Procedural Success and Success at 3-months
Box-plot showing immediate procedural success (24hrs post ablation) and success at 3 months follow up in the warfarin (n = 13) and no-warfarin (n = 33) group. Both acute and long-term ablation success was similar in both groups (warfarin versus non-warfarin 69.2% versus 72.7%, p = 0.81 and 72.7% versus 58.6%, p =0.37). 
